Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma. PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.

NCT Number	NCT00626990
Lead Sponsor	European Organisation for Research and Treatment of Cancer - EORTC Collaborators: NCIC Clinical Trials Group, Radiation Therapy Oncology Group, Medical Research Council, Merck Sharp & Dohme LLC
Conditions	Brain and Central Nervous System Tumors
Enrollment	751 participants
Start Date	2007-12
Primary Completion	2018-09-05 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2023-09-11